Percutaneous 17ß-estradiol replacement therapy in hypertensive postmenopausal women

Brazilian Journal of Medical and Biological Research

Volumn 30, Issue 9, 1997, Pages 1047-1053

  Osorio Wender M C ^a   Vitola, D ^c   Spritzer, P M ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

Author keywords

17 estradiol; FSH; Hormone replacement therapy; Hypertension; LH; Menopause

Indexed keywords

ANTITHROMBIN III; CHOLESTEROL; ESTRADIOL; FOLLITROPIN; GUANABENZ ACETATE; LIPOPROTEIN; LUTEINIZING HORMONE; RENIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESTROGEN THERAPY; FEMALE; GEL; HEART RATE; HUMAN; HYPERTENSION; PLASMA RENIN ACTIVITY; POSTMENOPAUSE; SYSTOLIC BLOOD PRESSURE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; AGED; BLOOD PRESSURE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPERTENSION; LUTEINIZING HORMONE; MIDDLE AGED; POSTMENOPAUSE;

EID: 0030851669     PISSN: 0100879X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-879X1997000900001     Document Type: Article

References (24)

1. Steingold KA, Laufer L & Chetkowski RJ (1985). Treatment of hot flashes with transdermal estradiol administration. Journal of Clinical Endocrinology and Metabolism, 61: 627-632.
2. Bathia NN, Bergman A & Karam MM (1989). Effects of estrogen on urethral function in women with urinary incontinence. American Journal of Obstetrics and Gynecology, 160: 176-181.
3. Lindsay R, Hart DM & Clark DM (1984). The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstetrics and Gynecology, 63: 759-763.
4. Christiansen C & Riis BJ (1990). 17ß-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. Journal of Clinical Endocrinology and Metabolism, 71: 836-841.
5. Bush TL, Barret-Connor E & Cowan LD (1987). Cardiovascular mortality and contraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation, 75: 1102-1119.
6. Stampfer MJ, Colditz GA, Willet WC, Manson JE, Rosner B, Speizer FE & Hennekens CH (1991). Postmenopausal estrogen therapy and cardiovascular disease: ten year follow-up from the Nurse's Health Study. New England Journal of Medicine, 325: 756-762.
7. Petitti DB, Perlman JA & Sidnei S (1987). Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek study. Obstetrics and Gynecology, 70: 289-293.
8. Henderson BE, Paganini-Hill A & Ross RK (1991). Decreased mortality in users of estrogen replacement therapy. Archives of Internal Medicine, 151: 75-78.
9. Kornhauser C, Malacara JM, Donato F & Botello D (1994). High prevalence of arterial hypertension in women over 50 years of age in the city of Leon, Guanajuato. Revista de Investigacion Clinica, 46: 287-294.
10. Staessen J, Bulpitt CJ, Fagard R, Lijnen P & Amery A (1989). The influence of menopause on blood pressure. Journal of Hypertension, 1: 361-364.
11. Lobo RA (1987). Different types of estrogens and progestogens. Obstetrics and Gynecology Clinics of North America, 14: 143-167.
12. Ganten D, Takahashi S, Lindpainter K & Mullins J (1991). Genetic basis of hypertension. The renin-angiotensin paradigm. Hypertension, 18 (Suppl III): 109-114.
13. Hassager C, Strom V, Guyene TT & Christiansen C (1987). The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation, 76: 753-758.
14. Von Eiff AW, Plotz EJ, Beck KJ & Czernik A (1971). The effects of estrogens and progestins on blood pressure regulation of normotensive women. American Journal of Obstetrics and Gynecology, 4: 31-47.
15. Osório MC, Vitola D & Spritzer PM (1992). Gel de estradiol 17ß no tratamento de pacientes pós-menopáusicas hipertensas. Arquivos Brasileiros de Endocrinologia e Metabolismo, 36: 40-43.
16. Wren BG, Brown LB & Routledge DA (1982). Differential clinical response to oestrogens after menopause. Medical Journal of Australia, 2: 329-332.
17. Philippe E, Faguer A, Charpin C, Loubière R, Mascarel A, Leduc F, Dupin Ph, Hemet J, Vauzelle JL, Bigel P, Bapin M, Pages A, Lenne Y, Laguillaumie B, De Lignières B & Gillet JY (1993). L'endomètre sous traitement hormonal substitutif de la menopause par estradiol percutané et progestérone micronisée à faible dose Pathologica, 85: 465-487.
18. Gillet JV, Faguer B, Andre G, Magnin G, De Lignières B & Philippe E (1994). Recherche d'un traitement hormonal substitutif "sans règles" avec la progesterone micronisée orale. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction, 23: 407-412.
19. Holst J, Cajander S, Carlstrom K, Damber MG & von Shoultz B (1983). A comparison of liver protein induction in postmenopausal women during oral and percutaneous oestrogen replacement therapy. British Journal of Obstetrics and Gynaecology, 90: 355-360.
20. De Lignières B, Basdevant A, Thomas G, Thalabard JC, Bodadr CM, Conard J, Guyenne TT, Mairon N, Corvel P, GuyGrand B, Mauvais-Jarvis P & Sitruk-Ware R (1986) Biological effects of estradiol-17ß in post-menopausal women: oral versus percutaneous administration. Journal of Clinical Endocrinology and Metabolism, 62: 536-541.
21. De Lignières B, Conard J, Samama M, Basdevant A & Guy-Grand B (1983). Differential AT III response to oral and parenteral administration of 17ß-estradiol. Thrombosis and Haemostasis, 49: 245.
22. Lobo RA (1990). Cardiovascular implications of estrogen replacement therapy. Obstetrics and Gynecology, 75 (Suppl 4): 18s-25s.
23. Lip GYH, Beevers M, Churchill D & Beevers DG (1994). Hormone replacement therapy and blood pressure in hypertensive women. Journal of Human Hypertension, 8: 491-494.
24. Clisham PR, Ceddars MI, Greendale G, Fu YS, Gambone J & Judd HL (1992). Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns. Obstetrics and Gynecology, 79: 196-201.